- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01055834
A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
A Bioequivalence Study of Different Formulations of SEP-190 and Food Effect Study in Japanese Healthy Adult Males
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tokyo
-
Sumida, Tokyo, Japan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria;
- Participants who are given a full explanation about the objective and details of this study before starting screening and give written consent based on their free will
- Japanese healthy male adult volunteers
- Participants who are between 20 and 54 years of age at the time of obtaining written consent
- Body Mass Index (BMI) is between 18.5 kg/m2 and 25.0 kg/m2 at the time of screening
Exclusion criteria;
- Participants with a present illness or history of allergy to drug or food, or seasonal allergy
- Participants who have a known history of any gastrointestinal surgery (e.g., hepatectomy, nephrotomy, etc.) that may affect pharmacokinetic evaluation
- Participants who are found to have clinically abnormal findings in medical history, symptoms and clinical findings, vital signs, electrocardiograms, or laboratory parameters of which require medical treatment(s), or impaired organ functions
- Participants who have a known or suspected history of alcohol or drug abuse, or those who have a positive urine drug screening
- Participants who are positive for hepatitis B surface antigen (HBs antigen), hepatitis C virus (HCV) antibody, or those who are human immunodeficiency virus (HIV)-positive, or those who are positive for syphilis screen
- Participants who underwent blood transfusion within 12 weeks prior to, those whose 400 mL or more of whole blood was collected within 12 weeks prior to, or those whose 200 mL or more of whole blood was collected within 4 week prior to study drug administration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eszopiclone 3 mg tablet
|
Group A Period I, Group B Period II: Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting >=10 hours. Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug. Group B Period III: Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast. Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast & the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration. |
Experimental: Eszopiclone 1 mg tablet
|
Group A Period II, Group B Period I: Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours. Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic Parameter (Bioequivalence): Maximal Drug Concentration (Cmax)
Time Frame: immediately before administration & 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose
|
Pharmacokinetic parameter: maximal drug concentration (Cmax) was measured in order to confirm bioequivalence.
Cmax was measured in nanograms per milliliter (ng/mL).
Blood sampling was calculated immediately before administration of the study drug and 24 hours after administration of the study drug (0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose).
|
immediately before administration & 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose
|
Pharmacokinetic Parameter (Bioequivalence): Area Under the Plasma Concentration- Time Curve From Time 0 to Time 24 Hours (AUC[0-24])
Time Frame: immediately before administration & 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose
|
Pharmacokinetic parameter: Area under the plasma concentration- time curve from time 0 (administration of the drug) to time 24 hours was measured in order to confirm bioequivalence.
AUC was measured in nanogram hours per milliliter (ng*h/mL).
Blood sampling was calculated immediately before administration of the study drug and 24 hours after administration of the study drug (0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose).
|
immediately before administration & 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose
|
Pharmacokinetic Parameter (Food Effect): Maximal Drug Concentration (Cmax)
Time Frame: immediately before administration & 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose
|
Pharmacokinetic parameter: maximal drug concentration (Cmax) was measured in order to investigate the effect of food.
Cmax was measured in nanograms per milliliter (ng/mL) and was measured under fasted and fed conditions.
Blood sampling was calculated immediately before administration of the study drug and 24 hours after administration of the study drug (0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose).
|
immediately before administration & 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose
|
Pharmacokinetic Parameter (Food Effect): Area Under the Plasma Concentration- Time Curve From Time 0 to Time 24 Hours (AUC[0-24])
Time Frame: immediately before administration & 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose
|
Pharmacokinetic parameter: Area under the plasma concentration- time curve from time 0 (administration of the drug) to time 24 hours was measured in order to investigate the effect of food.
AUC was measured in nanogram hours per milliliter (ng*h/mL) and was measured under fasted and fed conditions.
Blood sampling was calculated immediately before administration of the study drug and 24 hours after administration of the study drug (0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose).
|
immediately before administration & 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 hours post-dose
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kenya Nakai, Japan Clinical Pharmacology, Eisai Co., Ltd.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 190-102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
National Yang Ming UniversityBened Biomedical Co., Ltd.Not yet recruiting
-
Leiden University Medical CenterNot yet recruiting
-
Weill Medical College of Cornell UniversityMARPACCompleted
-
Regenstrief Institute, Inc.Merck Sharp & Dohme LLC; National Sleep FoundationUnknownInsomniaUnited States
-
Posit Science CorporationUniversity of California, San FranciscoCompleted
-
University of UtahNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Minneapolis Veterans Affairs Medical CenterWithdrawn
-
GlaxoSmithKlineWithdrawn
-
Coeruleus Ltd.Completed
-
PfizerCompleted
Clinical Trials on Eszopiclone 3 mg
-
Eisai Co., Ltd.Completed
-
SunovionCompleted
-
University of Sao Paulo General HospitalRecruitingInsomnia | Obstructive Sleep ApneaBrazil
-
Dr. Reddy's Laboratories LimitedCompleted
-
University of Medicine and Dentistry of New JerseySunovionCompletedParkinson's Disease | InsomniaUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
Eisai Co., Ltd.Completed
-
University of PittsburghSunovion; American Academy of Sleep MedicineCompletedSleep Initiation and Maintenance Disorders | Primary InsomniaUnited States
-
University of California, Los AngelesNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
University of California, San DiegoAmerican Academy of Sleep MedicineRecruitingObstructive Sleep ApneaUnited States